Human CD25/IL-2 R alpha Quantikine ELISA Kit
| Name | Human CD25/IL-2 R alpha Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DR2A00 |
| Category | ELISA Kit |
| Prices | $509.00, $2,440.00, $16,540.00 |
| Sizes | 1 kit, 1 pack (6 Plates), 1 pack (50 Plates) |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (10 uL), Serum (13 uL), EDTA Plasma (13 uL), Heparin Plasma (13 uL) |
| Sensitivity | 10 pg/mL |
| Range | 78.0 - 5,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Heparin Plasma) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human IL-2 sR alpha Immunoassay is a 3.5 hour solid phase ELISA designed to measure IL-2 sR alpha in cell culture supernates, serum, and plasma |
| Gene | IL2RA |
| Supplier Page | Shop |
Product images
Product References
Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic - Incidence and Risk Factors for Developing Dengue-Associated Hemophagocytic
Ellis EM, Sharp TM, Perez-Padilla J, Gonzalez L, Poole-Smith BK, Lebo E, Baker C, Delorey MJ, Torres-Velasquez B, Ochoa E, Rivera-Garcia B, Diaz-Pinto H, Clavell L, Puig-Ramos A, Janka GE, Tomashek KM. PLoS Negl Trop Dis. 2016 Aug 24;10(8):e0004939. doi:
Stability of cytokines, chemokines and soluble activation markers in unprocessed - Stability of cytokines, chemokines and soluble activation markers in unprocessed
Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Cytokine. 2016 Aug;84:17-24.
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy - Efficacy, durability, and response predictors of low-dose interleukin-2 therapy
Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ. Blood. 2016 Jul 7;128(1):130-7.
Augmented efficacy with the combination of blockade of the Notch-1 pathway, - Augmented efficacy with the combination of blockade of the Notch-1 pathway,
Yu P, Petrus MN, Ju W, Zhang M, Conlon KC, Nakagawa M, Maeda M, Bamford RN, Waldmann TA. Leukemia. 2015 Mar;29(3):556-66.
Elevated levels of CXCL10 in the Periodic Fever, Aphthous stomatitis, Pharyngitis - Elevated levels of CXCL10 in the Periodic Fever, Aphthous stomatitis, Pharyngitis
Forsvoll J, Kristoffersen EK, Oymar K. Pediatr Rheumatol Online J. 2013 Oct 17;11(1):38.
Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase - Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase
Marzec M, Halasa K, Liu X, Wang HY, Cheng M, Baldwin D, Tobias JW, Schuster SJ, Woetmann A, Zhang Q, Turner SD, Odum N, Wasik MA. J Immunol. 2013 Dec 15;191(12):6200-7.
Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an - Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an
Kassianos AJ, Hardy MY, Ju X, Vijayan D, Ding Y, Vulink AJ, McDonald KJ, Jongbloed SL, Wadley RB, Wells C, Hart DN, Radford KJ. Eur J Immunol. 2012 Jun;42(6):1512-22.
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with - Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with
Singh R, Zhang Y, Pastan I, Kreitman RJ. Clin Cancer Res. 2012 Jan 1;18(1):152-60.
Phase 2 study of cladribine followed by rituximab in patients with hairy cell - Phase 2 study of cladribine followed by rituximab in patients with hairy cell
Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Blood. 2011 Oct 6;118(14):3818-23.
A novel role for IL-22R1 as a driver of inflammation. - A novel role for IL-22R1 as a driver of inflammation.
Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, Shirota H, Klinman DM, Dunleavy K, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA. Blood. 2011 Jan 13;117(2):575-84.